Summary as follows:-
Column 1 0 Oppenheimer Update 21 March 2018
Closing Price: $6.11
Market Cap : $578.3M
Rating; OUTPERFORM; Prio( no change)
Price Target: $16.00
MESO: OPCO Healthcare Conference Update1 Wednesday, at the 28th Annual Oppenheimer & Co. Healthcare Conference, Mesoblast’s CMO Donna Skerrett provided a corporate overview and fielded investor questions. As outlined in the presentation, Mesoblast has begun to make preparations for a US commercial launch of MSC-100-IV in pediatric steroid-refractory acute graft-versus-host disease (aGVHD) following recently announced positive top-line results from its Phase 3 trial. We believe the company could file for regulatory approval in late 2018 based on a combination of day 28 results and extended (six-month) outcomes. Additionally, in 2H18, we expect to see top-line data from an NIH-sponsored randomized trial of MPC-150-IM in end-stage heart failure. Reiterate Outperform.
GLTAH
Add to My Watchlist
What is My Watchlist?
